Transforming Rare Antibody Discovery to Make Novel Medicines Possible

About Us

Eira Bio harnesses synthetic biology and evolution to make the most challenging discoveries routine. 

We are pioneering the next generation of antibody-based biologics targeting challenging multi-pass membrane proteins to address unmet needs in the treatment of disease.

Our powerful, scalable yeast-based platforms enable the discovery, evolution, and optimization of precision antibodies against complex multi-pass membrane targets, including GPCRs, ion channels, and solute transporters that have historically been inaccessible. Our technology unlocks new therapeutic opportunities for diseases with high unmet need. 

Our Science

Eira Bio is transforming drug discovery and development for challenging multi-pass membrane targets by combining cutting edge synthetic biology and directed-evolution technologies with world-class drug development capabilities.

Synthetic Biology

Synthetic biology circuits enable identification of rare antibodies with high scale, efficiency, and precision.

Directed Evolution

Directed evolution platforms enable affinity maturation without the constraints of a predefined library.

Transformational Therapies

Unique antibodies against high-value targets enable new first and best-in-class therapeutics.

Meet the Team

  • Holger Wesche, Ph.D.

    Chief Scientific Officer

    LinkedIn

  • Thomas Galbo, Ph.D.

    Chief Executive Officer

    LinkedIn

  • Kevin Carlin, Ph.D.

    Associate Director,
    Protein Science

    LINKEDIN

  • Marcus Deichmann, Ph.D.

    Scientist,
    Synthetic Biology

    LinkedIn

  • Chen Fang, Ph.D.

    Principal Scientist,
    Protein Science

    LinkedIn

  • Bryan Lemon, Ph.D.

    Senior Vice President,
    Product Development

    LinkedIn

  • Mary Ellen Molloy, Ph.D.

    Director,
    In Vivo and Translational Science

    LinkedIn

  • Alex Javanpour, Ph.D.

    Scientist,
    Synthetic Biology

    LinkedIn

  • Shanling Shen

    Associate Scientist,
    Research

    LinkedIn

  • Laura Valenzuela

    Associate Scientist,
    In Vivo and Translational Science

    LinkedIn

  • Lexie Wang

    Senior Research Associate,
    Synthetic Biology

    LinkedIn

  • Kevin Wright, Ph.D.

    Senior Director,
    Research

    Linkedin

  • Michelle Nguyen

    Senior Research Associate, Protein Science

    Click Here

Our Founders

  • Mo Khalil, Ph.D.

    Professor,
    Harvard University

    LinkedIn

  • Chang Liu, Ph.D.

    Professor,
    UC Irvine

    LinkedIn

  • Nikit Patel, Ph.D.

    Scientist,
    Boston University

    LinkedIn

  • Arjun Ravikumar, Ph.D.

    Scientist,
    Boston University

    LinkedIn

  • Gordon Rix, Ph.D.

    Scientist,
    Boston University

    LinkedIn

  • Brandon Wong, Ph.D.

    Scientist,
    Boston University

    LinkedIn

Our Board

We’re always interested in meeting motivated and talented people who want to make an impact.


We move fast, think deeply, and care about doing meaningful work together. If you’re excited about using cutting-edge science to solve big problems, then reach out to us and follow us on LinkedIn.

Careers

Current Openings

Eira-15: Senior Research Associate/Associate Scientist, Protein Science - Purification

To apply please send your resume to resume@eirabio.com and refer to the job code in the subject line.

Investors

News

Featured
Nature
Nature

Check out this new paper in Nature from the Baker group and Xaira team in collaboration with K2 co-founder Chang Liu that highlights the powerful synergy between computational design and directed evolution using OrthoRep to develop precise high-affinity antibodies. Congratulations to all the authors!

Read More →
Harvard SEAS
Harvard SEAS

Our Co-Founder, Prof. Mo Khalil, is joining the Harvard SEAS faculty as the Hok Lam and Kathleen Kam Wong Professor of Bioengineering. Congrats Mo!

Read More →

Learn more about our work:

Ravikumar A, Arzumanyan GA, Obadi MKA, Javanpour AA, Liu CC. Scalable, continuous evolution of genes at mutation rates above genomic error thresholds. Cell, 175, 1946-1957 (2018). link

Wellner A, McMahon C, Gilman MSA, Clements JR, Clark S, Nguyen KM, Ho MH, Hu VJ, Shin J-E, Feldman J, Hauser BM, Caradonna TM, Wingler LM, Schmidt AG, Marks DS, Abraham J, Kruse AC, Liu CC. Rapid generation of potent antibodies by autonomous hypermutation in yeast. Nature Chemical Biology 17, 1057-1064 (2021). link

Rix G, Williams RL, Hu VJ, Spinner A, Pisera A, Marks DS, Liu CC. Continuous evolution of user-defined genes at 1-million-times the genomic mutation rate. Science 386, eadm9073 (2024). link

Bennett, NR, Watson, JL, Ragotte, RJ et al. Atomically accurate de novo design of antibodies with RFdiffusion. Nature (2025). https://doi.org/10.1038/s41586-025-09721-5 - link

Alcantar MA, Paulk AM, Moradi S et al. Mapping the evolution of computationally designed protein binders. bioRxiv (2025). link

Contact Us

Corporate Address
Eira Bio
1 Broadway
14th Floor
Cambridge, MA 02142

Research Address
Eira Bio
341 Oyster Point Blvd
South San Francisco, CA 94080

Email
info@eirabio.com

© 2025. All Rights Reserved.